核酸治療薬CDMO市場：タイプ、サービス、用途、エンドユーザー別-2025-2030年世界予測

核酸治療薬CDMO市場の2023年の市場規模は96億9,000万米ドルで、2024年には105億8,000万米ドルに達すると予測され、CAGR 9.64%で成長し、2030年には184億7,000万米ドルに達すると予測されています。

360iResearchの市場調査アナリストとして、核酸治療薬の研究開発・製造受託機関（CDMO）分野に焦点を当てるには、この新興国市場の範囲とニュアンスを理解することが不可欠です。mRNA、siRNA、アンチセンスオリゴヌクレオチドを含む核酸治療薬は、標的治療を再構築し、遺伝性疾患、がん、ウイルス感染の治療に大きな可能性を提供しています。これらの治療薬の必要性と応用は、遺伝的状態を直接標的とする能力によって強調され、従来の治療法では達成できなかった精密治療の選択肢を提供します。最終用途は、主に個別化医療を専門とするバイオテクノロジー企業や製薬企業であり、これらの新規治療法を含む研究開発パイプラインを拡大しています。市場成長の原動力は、遺伝子配列決定の技術的進歩、慢性疾患の有病率の増加、個別化医療への動向の高まりです。さらに、官民の投資により、こうした画期的な治療法の開発が加速しています。しかし、製造コストの高さ、拡張性の問題、厳しい規制環境、複雑な製造工程など、市場拡大の妨げになりかねない課題も残っています。チャンスは、費用対効果の高い製造技術の革新、送達メカニズムの強化、現在の限界を克服するための技術共有を促進するパートナーシップの開発にあります。CDMOは、統合デジタル・ソリューションや自動化など、拡張性、規制遵守、市場投入スピードを高める先進技術プラットフォームに投資することで、急増する需要を活用することができます。技術革新の重要な分野には、脂質ナノ粒子などの送達システムの改善や、標的細胞への核酸ペイロードの安全な送達を保証する安定した製剤技術の進化が含まれます。市場の性質に適応するには機敏なアプローチが必要であり、開発から商業生産までの包括的なサービスを含むポートフォリオを拡大する必要があります。このような市場力学と潜在的機会を理解することで、企業は核酸治療薬を前進させ、アンメット・メディカル・ニーズに対応し、この革新的な分野で力強い成長を促進するために、より良いポジションを確立することができます。

市場力学：急速に進化する核酸治療薬CDMO市場の主要市場インサイトを公開

核酸治療薬CDMO市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の遺伝性疾患の有病率の増加
  • 核酸研究を支える資金と投資の増加
• 市場抑制要因
  • 核酸療法の製造コストの高さ
• 市場機会
  • 核酸療法に対する規制当局の承認の増加
  • 個別化医療の拡大による高い可能性
• 市場の課題
  • 核酸療法の拡張性の限界

ポーターの5つの力：核酸治療薬CDMO市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：核酸治療薬CDMO市場における外部からの影響の把握

外部マクロ環境要因は、核酸治療薬CDMO市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析核酸治療薬CDMO市場における競合情勢の把握

核酸治療薬CDMO市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス核酸治療薬CDMO市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、核酸治療薬CDMO市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨核酸治療薬CDMO市場における成功への道筋を描く

核酸治療薬CDMO市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品上市、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で遺伝性疾患の罹患率が増加
    • 資金と投資の増加が核酸調査を支援
  • 抑制要因
    • 核酸治療の高生産コスト
  • 機会
    • 核酸治療の規制承認増加
    • 個別化医療の拡大による高い可能性
  • 課題
    • 核酸治療の拡張性は限られている
• 市場セグメンテーション分析
  • タイプ：感染症の蔓延拡大に伴うmRNA治療の継続的な進歩
  • 応用：がんの発生率の上昇により、革新的で効果的ながん治療の必要性が高まっています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 核酸治療薬CDMO市場：タイプ別

• DNAセラピューティクス
• RNAセラピューティクス

第7章 核酸治療薬CDMO市場：サービス別

• 分析および品質管理サービス
• 製造サービス
• プロセス開発と最適化

第8章 核酸治療薬CDMO市場：用途別

• 遺伝性疾患
• 感染症
• 腫瘍学

第9章 核酸治療薬CDMO市場：エンドユーザー別

• バイオテクノロジー企業
• 政府および学術調査機関
• 製薬会社

第10章 南北アメリカの核酸治療薬CDMO市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の核酸治療薬CDMO市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの核酸治療薬CDMO市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 富士フイルム富山化学とシンプロジェン、mRNA治療薬の生産強化に向け提携
  • Exothera、北米で先進的なRNA治療プラットフォーム「Ntensify」を発売、核酸医薬品開発を効率化
• 戦略分析と提言

企業一覧

• AGC Biologics Inc.
• Agilent Technologies, Inc.
• Ajinomoto Bio-Pharma Services
• Almac Group Ltd.
• Biomay AG
• BioSpring GmbH
• Catalent, Inc.
• Charles River Laboratories International, Inc.
• CordenPharma International GmbH
• Creative Biogene
• Danaher Corporation
• Eurofins Scientific SE
• Evonik Industries AG
• GenScript Biotech Corporation
• Lonza Group Ltd.
• Polypeptide Group AG
• Rentschler Biopharma SE
• Sanofi SA
• The Scripps Research Institute
• Univercells Group
• WuXi AppTec Co., Ltd.

LIST OF FIGURES

• FIGURE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET RESEARCH PROCESS
• FIGURE 2. NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NUCLEIC ACID THERAPEUTICS CDMO MARKET DYNAMICS
• TABLE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL AND QUALITY CONTROL SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT AND OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GOVERNMENT & ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 63. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 132. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 148. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 152. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 190. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 191. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2023

The Nucleic Acid Therapeutics CDMO Market was valued at USD 9.69 billion in 2023, expected to reach USD 10.58 billion in 2024, and is projected to grow at a CAGR of 9.64%, to USD 18.47 billion by 2030.

As a Market Research Analyst at 360iResearch focusing on the Nucleic Acid Therapeutics Contract Development and Manufacturing Organization (CDMO) sector, it's essential to understand the scope and nuances of this evolving industry. Nucleic acid therapeutics, including mRNA, siRNA, and antisense oligonucleotides, are reshaping targeted therapies, offering immense promise in treating genetic disorders, cancers, and viral infections. The necessity and application of these therapeutics are underscored by their ability to target genetic conditions directly, providing precision treatment options that traditional therapies may not achieve. End-use is primarily in biotechnology and pharmaceutical companies dedicated to personalized medicine, expanding their R&D pipelines to include these novel modalities. Market growth is driven by technological advancements in genetic sequencing, increasing prevalence of chronic diseases, and a rising trend towards personalized medicine. Moreover, public and private investments are accelerating the development of these groundbreaking therapies. However, challenges persist, such as high production costs, scalability issues, stringent regulatory environments, and complex manufacturing processes that may hinder market expansion. Opportunities lie in innovating cost-effective manufacturing techniques, enhancing delivery mechanisms, and developing partnerships that facilitate technology sharing to overcome current limitations. CDMOs can capitalize on the burgeoning demand by investing in advanced technology platforms that enhance scalability, regulatory compliance, and speed to market, such as integrated digital solutions and automation. Critical areas of innovation include improving delivery systems, such as lipid nanoparticles, and evolving stable formulation technologies that ensure the safe delivery of nucleic acid payloads to targeted cells. Adapting to the market's nature requires an agile approach, expanding portfolios to include comprehensive services spanning from development to commercial manufacturing. By understanding these market dynamics and potential opportunities, businesses can better position themselves to advance nucleic acid therapeutics, addressing unmet medical needs and driving robust growth within this innovative sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Nucleic Acid Therapeutics CDMO Market

The Nucleic Acid Therapeutics CDMO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of genetic disorders worldwide
  • Increasing funding and investments support nucleic acid research
• Market Restraints
  • High production costs of nucleic acid therapies
• Market Opportunities
  • Rising regulatory approvals for nucleic acid therapies
  • High potential with the expansion of personalized medicine
• Market Challenges
  • Limited scalability of nucleic acid therapies

Porter's Five Forces: A Strategic Tool for Navigating the Nucleic Acid Therapeutics CDMO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Nucleic Acid Therapeutics CDMO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Nucleic Acid Therapeutics CDMO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Nucleic Acid Therapeutics CDMO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Nucleic Acid Therapeutics CDMO Market

A detailed market share analysis in the Nucleic Acid Therapeutics CDMO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Nucleic Acid Therapeutics CDMO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Nucleic Acid Therapeutics CDMO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Nucleic Acid Therapeutics CDMO Market

A strategic analysis of the Nucleic Acid Therapeutics CDMO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Nucleic Acid Therapeutics CDMO Market, highlighting leading vendors and their innovative profiles. These include AGC Biologics Inc., Agilent Technologies, Inc., Ajinomoto Bio-Pharma Services, Almac Group Ltd., Biomay AG, BioSpring GmbH, Catalent, Inc., Charles River Laboratories International, Inc., CordenPharma International GmbH, Creative Biogene, Danaher Corporation, Eurofins Scientific SE, Evonik Industries AG, GenScript Biotech Corporation, Lonza Group Ltd., Polypeptide Group AG, Rentschler Biopharma SE, Sanofi SA, The Scripps Research Institute, Univercells Group, and WuXi AppTec Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Nucleic Acid Therapeutics CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across DNA Therapeutics and RNA Therapeutics.
• Based on Service, market is studied across Analytical and Quality Control Services, Manufacturing Services, and Process Development and Optimization.
• Based on Application, market is studied across Genetic Disorders, Infectious Diseases, and Oncology.
• Based on End-user, market is studied across Biotech Companies, Government & Academic Research Institutes, and Pharmaceutical Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of genetic disorders worldwide
    • 5.1.1.2. Increasing funding and investments support nucleic acid research
  • 5.1.2. Restraints
    • 5.1.2.1. High production costs of nucleic acid therapies
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising regulatory approvals for nucleic acid therapies
    • 5.1.3.2. High potential with the expansion of personalized medicine
  • 5.1.4. Challenges
    • 5.1.4.1. Limited scalability of nucleic acid therapies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Ongoing advancements in mRNA therapeutics with rising prevalence of infectious diseases
  • 5.2.2. Application: Rising incidence of cancer push the need for innovative and effective cancer treatments
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Nucleic Acid Therapeutics CDMO Market, by Type

• 6.1. Introduction
• 6.2. DNA Therapeutics
• 6.3. RNA Therapeutics

7. Nucleic Acid Therapeutics CDMO Market, by Service

• 7.1. Introduction
• 7.2. Analytical and Quality Control Services
• 7.3. Manufacturing Services
• 7.4. Process Development and Optimization

8. Nucleic Acid Therapeutics CDMO Market, by Application

• 8.1. Introduction
• 8.2. Genetic Disorders
• 8.3. Infectious Diseases
• 8.4. Oncology

9. Nucleic Acid Therapeutics CDMO Market, by End-user

• 9.1. Introduction
• 9.2. Biotech Companies
• 9.3. Government & Academic Research Institutes
• 9.4. Pharmaceutical Companies

10. Americas Nucleic Acid Therapeutics CDMO Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Nucleic Acid Therapeutics CDMO Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Nucleic Acid Therapeutics CDMO Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. FUJIFILM Toyama Chemical and Synplogen Forge Alliance to Enhance mRNA Therapeutics Production
  • 13.3.2. Exothera Launches Advanced RNA Therapeutics Platform 'Ntensify' in North America, Streamlining Nucleic Acid Drug Development
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AGC Biologics Inc.
• 2. Agilent Technologies, Inc.
• 3. Ajinomoto Bio-Pharma Services
• 4. Almac Group Ltd.
• 5. Biomay AG
• 6. BioSpring GmbH
• 7. Catalent, Inc.
• 8. Charles River Laboratories International, Inc.
• 9. CordenPharma International GmbH
• 10. Creative Biogene
• 11. Danaher Corporation
• 12. Eurofins Scientific SE
• 13. Evonik Industries AG
• 14. GenScript Biotech Corporation
• 15. Lonza Group Ltd.
• 16. Polypeptide Group AG
• 17. Rentschler Biopharma SE
• 18. Sanofi SA
• 19. The Scripps Research Institute
• 20. Univercells Group
• 21. WuXi AppTec Co., Ltd.